Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


No More Nucs: Merck & Co. Cedes HCV Market To Gilead, AbbVie

Executive Summary

Pharma ends HCV development, pulling plug on next-generation two-drug and three-drug combos for hepatitis C and rendering the $3.9bn buyout of Idenix in 2014 a failed gambit.


Related Content

Merck's New Pricing Pledge Shows Style Over Substance
The Year's Clinical Trials In Review: Big Misses In 2017
With J&J’s Departure From HCV, Gilead Stands Alone In ‘Nuc’ Field
AbbVie's Mavyret Is First 8-Week Pan-Genotypic Combination For HCV
Merck's Write-Down Of Phase II Nuc Illustrates Current Reality In HCV
Gilead Offers Split Guidance For HCV; Expects Further Decline In 2017
INFOGRAPHIC: Hepatitis C Market Still Has Room To Grow
Merck Reaches Hepatitis C Market With Zepatier
Merck's HCV Strategy Might Be: Get To Market, Then Improve Incrementally
Merck in $3.85bn Idenix buy to bolster hep C outlook


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts